Literature DB >> 26228516

Randomized controlled trial comparing esophageal dilation to no dilation among adults with esophageal eosinophilia and dysphagia.

R T Kavitt1, F Ates2, J C Slaughter3, T Higginbotham2, B D Shepherd2, E L Sumner2, M F Vaezi2.   

Abstract

The role of esophageal dilation in patients with esophageal eosinophilia with dysphagia remains unknown. The practice of dilation is currently based on center preferences and expert opinion. The aim of this study is to determine if, and to what extent, dysphagia improves in response to initial esophageal dilation followed by standard medical therapies. We conducted a randomized, blinded, controlled trial evaluating adult patients with dysphagia and newly diagnosed esophageal eosinophilia from 2008 to 2013. Patients were randomized to dilation or no dilation at time of endoscopy and blinded to dilation status. Endoscopic features were graded as major and minor. Subsequent to randomization and endoscopy, all patients received fluticasone and dexlansoprazole for 2 months. The primary study outcome was reduction in overall dysphagia score, assessed at 30 and 60 days post-intervention. Patients with severe strictures (less than 7-mm esophageal diameter) were excluded from the study. Thirty-one patients were randomized and completed the protocol: 17 randomized to dilation and 14 to no dilation. Both groups were similar with regard to gender, age, eosinophil density, endoscopic score, and baseline dysphagia score. The population exhibited moderate to severe dysphagia and moderate esophageal stricturing at baseline. Overall, there was a significant (P < 0.001) but similar reduction in mean dysphagia score at 30 and 60 days post-randomization compared with baseline in both groups. No significant difference in dysphagia scores between treatment groups after 30 (P = 0.93) or 60 (P = 0.21) days post-intervention was observed. Esophageal dilation did not result in additional improvement in dysphagia score compared with treatment with proton pump inhibitor and fluticasone alone. In patients with symptomatic esophageal eosinophilia without severe stricture, dilation does not appear to be a necessary initial treatment strategy.
© 2015 International Society for Diseases of the Esophagus.

Entities:  

Keywords:  eosinophilic esophagitis; esophageal dilation; esophageal eosinophilia; randomized controlled trial

Mesh:

Substances:

Year:  2015        PMID: 26228516     DOI: 10.1111/dote.12398

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  13 in total

1.  Esophageal Dilation as the Primary Treatment for Eosinophilic Esophagitis.

Authors:  David A Katzka
Journal:  Gastroenterol Hepatol (N Y)       Date:  2019-06

2.  Control of inflammation decreases the need for subsequent esophageal dilation in patients with eosinophilic esophagitis.

Authors:  T M Runge; S Eluri; J T Woosley; N J Shaheen; E S Dellon
Journal:  Dis Esophagus       Date:  2017-07-01       Impact factor: 3.429

3.  Current Diagnostic and Treatment Strategies for Eosinophilic Esophagitis.

Authors:  Anna M Lipowska; Robert T Kavitt
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-09

Review 4.  Recent discoveries and emerging therapeutics in eosinophilic esophagitis.

Authors:  Aakash Goyal; Edaire Cheng
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

5.  Dilation of Pediatric Eosinophilic Esophagitis: Adverse Events and Short-term Outcomes.

Authors:  Calies Menard-Katcher; Glenn T Furuta; Robert E Kramer
Journal:  J Pediatr Gastroenterol Nutr       Date:  2017-05       Impact factor: 2.839

6.  British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) joint consensus guidelines on the diagnosis and management of eosinophilic oesophagitis in children and adults.

Authors:  Anjan Dhar; Hasan N Haboubi; Stephen E Attwood; Marcus K H Auth; Jason M Dunn; Rami Sweis; Danielle Morris; Jenny Epstein; Marco R Novelli; Hannah Hunter; Amanda Cordell; Sharon Hall; Jamal O Hayat; Kapil Kapur; Andrew Robert Moore; Carol Read; Sarmed S Sami; Paul J Turner; Nigel J Trudgill
Journal:  Gut       Date:  2022-05-23       Impact factor: 31.793

Review 7.  Mechanisms and clinical management of eosinophilic oesophagitis: an overview.

Authors:  Luc Biedermann; Alex Straumann
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-10-17       Impact factor: 73.082

Review 8.  Esophageal dilation with either bougie or balloon technique as a treatment for eosinophilic esophagitis: a systematic review and meta-analysis.

Authors:  Michael Dougherty; Thomas M Runge; Swathi Eluri; Evan S Dellon
Journal:  Gastrointest Endosc       Date:  2017-04-28       Impact factor: 10.396

9.  Systematic review and meta-regressions: management of eosinophilic esophagitis requires histologic assessment.

Authors:  J W Chang; R Y Yeow; A K Waljee; J H Rubenstein
Journal:  Dis Esophagus       Date:  2018-08-01       Impact factor: 2.822

10.  Savary Dilation Is Safe and Effective Treatment for Esophageal Narrowing Related to Pediatric Eosinophilic Esophagitis.

Authors:  Abdulrahman Al-Hussaini
Journal:  J Pediatr Gastroenterol Nutr       Date:  2016-11       Impact factor: 2.839

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.